How We Rate Peptide Evidence — The PeptideWise Four-Tier Framework

Every peptide profile on PeptideWise carries an explicit evidence tier at the top of the page. The tier tells you, in one symbol, how strong the underlying research is — so you can calibrate how much weight to put on the rest of the profile before you read the details. This page documents the framework: what each tier means, what criteria move a peptide from one tier to another, and how to use the tiers when comparing compounds.

Why an Evidence Tier System

Peptide research spans an enormous range of evidence quality — from FDA-approved drugs supported by 17,000-patient cardiovascular outcomes trials to compounds with only animal data, mechanistic speculation, and forum reports. Without a structured framework, a single profile page reads the same regardless of which end of that spectrum the underlying evidence sits on. Readers either have to be experts at evaluating biomedical literature themselves or risk treating speculative claims as established fact.

The four-tier system does not replace reading the evidence — the citations, trial designs, and safety data still matter — but it provides a categorical signal that orients the reader before they encounter any specific claim. We chose four tiers (rather than letter grades) deliberately: the categorical distinctions matter more than apparent precision.

The Four Tiers

Tier 1 — FDA-Approved (or equivalent major regulator)

Criteria. The peptide has been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or another major regulator for at least one human indication. This requires multiple completed Phase 3 trials with statistically significant efficacy and an acceptable safety profile, peer-reviewed publication of the pivotal data, and regulatory review of the full chemistry/manufacturing/controls (CMC) data.

Examples on PeptideWise: Semaglutide (Wegovy / Ozempic / Rybelsus), Tirzepatide (Mounjaro / Zepbound), Sermorelin (Geref, pediatric GHD), Tesamorelin (Egrifta, HIV-associated lipodystrophy), PT-141 (Vyleesi, premenopausal HSDD).

What this tier means. The compound has cleared the highest standard of evidence available — including cardiovascular and other outcomes data in many cases. Risks are documented in the FDA label. This does not mean the compound is risk-free or appropriate for every reader; the safety section of each profile is still where you make individual decisions.

Tier 2 — Strong Human Evidence (not yet FDA-approved)

Criteria. Multiple completed human randomized controlled trials (Phase 2 or Phase 3) with peer-reviewed publication, but the compound has not yet received FDA approval. This typically means a regulatory submission is anticipated or in progress, or the compound is approved abroad but not in the U.S.

Examples on PeptideWise: Retatrutide (investigational triple agonist; Phase 3 TRIUMPH program ongoing), CagriSema (Novo Nordisk REDEFINE Phase 3 published in NEJM 2025; first regulatory filing anticipated 2026).

What this tier means. The clinical efficacy and short-term safety profile are well characterized in published human trials. The remaining uncertainty is around long-term safety, post-approval real-world performance, and final regulatory labeling.

Tier 3 — Mechanism Plus Translational Evidence

Criteria. A well-characterized mechanism of action, supportive animal evidence across multiple independent laboratories, and at least some early human data (Phase 1 pharmacokinetic and tolerability studies, small Phase 2 trials, or off-label clinical experience documented in peer-reviewed literature). Evidence is meaningfully stronger than animal data alone but does not yet meet the threshold for Tier 2.

Examples on PeptideWise: BPC-157 (extensive preclinical; first systematic reviews published 2026 with limited human data), GHK-Cu (preclinical and cosmetic clinical literature), Ipamorelin (Phase 2 clinical trial data for postoperative ileus), CJC-1295 (Phase 1/2 data in healthy adults).

What this tier means. The mechanism is real and the animal evidence is consistent. Human evidence is suggestive but not definitive. Treat published claims about specific human outcomes with appropriate caution.

Tier 4 — Animal or In-Vitro Evidence Only

Criteria. The compound has been studied preclinically — in animal models, isolated cells, or biochemical systems — but no published human clinical trial data exists. Any extrapolation to human outcomes is mechanistic speculation.

Examples on PeptideWise: Some entries in the cognitive and longevity categories where research has remained preclinical. Tier classification is documented in each profile's evidence section.

What this tier means. Read with the most caution. Animal evidence does not reliably predict human outcomes, and the history of biomedicine includes many compounds with promising preclinical data that failed in human trials. If a profile is Tier 4, the most honest claim about its human effects is "we don't know."

How to Use the Tiers

The tier helps you do three things:

Calibrate confidence. A Tier 1 claim ("Wegovy produces ~15% mean weight loss at 68 weeks") is supported by FDA-reviewed Phase 3 data. A Tier 4 claim ("This compound may have anti-aging effects") is mechanistic speculation. Both can appear in the same paragraph if the writing is sloppy — the tier prevents them from being read with the same confidence.
Compare across compounds. When evaluating two peptides that may produce similar effects, the tier difference is often the most important piece of information. Semaglutide (Tier 1) and CagriSema (Tier 2) both target GLP-1, but the difference in evidence quality matters when deciding what to read first.
Spot the gap between mechanism and outcomes. Many peptides have well-characterized mechanisms (which is a mechanism claim, not an outcomes claim) but limited evidence of the specific outcomes a reader cares about. The tier system makes this gap visible.

How We Update Tiers

A tier can move up when significant new evidence is published — most commonly when a peptide receives FDA approval (Tier 2 → Tier 1), when Phase 3 trial results are published in a major journal (Tier 3 → Tier 2), or when the first Phase 1/2 human data is published (Tier 4 → Tier 3).

A tier can move down when previously cited research is retracted (as happened with the Dihexa foundational paper in April 2025), when systematic review evidence downgrades the body of work, or when replication failures emerge. The "Last updated" date on each profile reflects the most recent material review.

We do not move tiers in response to social-media discussion, promotional material from manufacturers or vendors, or non-peer-reviewed sources. The tier reflects the published scientific record.

What This Framework Is Not

Not a safety rating. A high tier does not mean the compound is safe for any individual. Read the safety section of each profile, and discuss with a qualified clinician.
Not an efficacy ranking. A high tier does not mean the compound produces the largest effect. It means the evidence behind any effect claim is well established.
Not a recommendation. PeptideWise does not recommend any compound for any individual. The tier system is a transparency tool, not a prescription.
Not a substitute for reading the evidence. The citations in each profile are the actual data. The tier is a shortcut, not a replacement.

Frequently Asked Questions

Why does PeptideWise use a tier system rather than letter grades?

Letter grades (A–F) tend to imply continuous quality on a single dimension, which obscures the categorical distinction between, say, an FDA-approved drug and an investigational compound with promising Phase 2 data. The four-tier system makes the categorical distinction explicit at the top of every profile so readers can immediately calibrate how much weight to put on the rest of the page.

Does a higher tier mean the peptide is "better" or "safer"?

No. Tier reflects the strength and quality of the evidence available, not the magnitude of effect or the safety profile. A Tier 3 peptide may have a strong mechanism, animal data, and a favorable safety record without yet having Phase 3 human RCTs. A Tier 1 peptide is FDA-approved but may still carry significant risks. Use the tier to calibrate how confident you can be in the published claims, then read the full safety section.

What if a peptide has different evidence levels for different outcomes?

This is common — for example, a peptide may have Tier 2 evidence for one indication and Tier 4 evidence for another. Where this distinction is meaningful, we note it within the relevant section of the profile and use the strongest applicable tier for the headline rating. Future iterations of this framework may add per-outcome ratings for the most important cases.

How do you decide when to update a peptide's tier?

A tier can move up when significant new evidence is published (e.g., a Phase 3 trial published in NEJM, an FDA approval, a high-quality systematic review). It can move down if previously cited research is retracted, fails replication, or is downgraded by an updated systematic review. The "Last updated" date on each profile reflects the most recent material review.

Are tiers comparable across PeptideWise and other peptide sites?

Other educational sites use various rating systems — Examine.com uses A–F letter grades per outcome, and The Peptide List uses a four-tier framework focused on FDA status. The PeptideWise tiers are most comparable to The Peptide List's framework but extend the criteria with explicit guidance on systematic-review and replication evidence. Comparing across sites is reasonable for orientation; reading the underlying evidence is what actually matters.

Can I see all the peptides in a particular tier?

Yes. Each peptide profile carries an evidence-tier label in its quick-facts header and an evidence badge in the registry listing. To browse by tier, scan the profile cards on the homepage and topical hub pages — the badge sits at the top of each card. A dedicated tier-filtered listing is on the roadmap.

How We Rate Peptide EvidenceThe PeptideWise Four-Tier Framework